ライフサイエンスコーパス: no significant difference in

1 There was also no significant difference in histologic findings between the

2 resulted in significantly greater cartilage volume loss and no significant difference in knee pain.

3 ral neuropathy (OR, 2.52; 95% CI, 1.43-4.43; P = .001), but no significant difference in the odds of arterial stiffness (

4 ersus 320 pg/mL; all P<0.01), more signs of congestion, but no significant difference in left ventricular ejection fracti

5 is study offers the first histologic evidence demonstrating no significant difference in vital bone formation or dimensio

6 The present study found no significant difference in the prevalence of VMA in eyes af

7 We found no significant difference in 1-year kidney graft survival (p

8 essure care was high in both treatment groups, and we found no significant difference in adherence to blood-pressure medi

9 Although we observed no significant difference in achieved systolic BP, AngII-trea

10 betaPKD1KO mice under a chow diet presented no significant difference in glucose tolerance or insulin sec

11 NTAX score was compared with CABG with a high SYNTAX score, no significant difference in mortality and combined death/str

12 Subjects with or without Gag P2/NC CS mutations showed no significant difference in viral loads.

13 a-analysis of the highest quality randomized studies showed no significant difference in mortality (n = 5 studies; odds r

14 al [CI]: 0.50 to 0.84; p = 0.001), although there was still no significant difference in TVR between the two groups (HR:

15 There was no significant difference in 3-year renal allograft survival

16 There was no significant difference in acute complications.

17 cterial communities showed temporal stability, as there was no significant difference in beta diversity values between th

18 There was no significant difference in body mass index between both tre

19 unt the index surgery and the subsequent 90 days, there was no significant difference in cost from either the payer ($10,

20 There was no significant difference in cumulative costs by the type of

21 There was no significant difference in detection of tumors larger than

22 ts in the overall cohort died within 30 days, but there was no significant difference in freedom from chronic lung allogr

23 There was no significant difference in GUSTO moderate/severe bleeding w

24 After adjustment, there was no significant difference in in-hospital mortality between ce

25 IL-4 and IL-2 in both MCI groups (P<0.001), while there was no significant difference in inflammatory markers between dem

26 There was no significant difference in Intensive Care Unit admissions,

27 There was no significant difference in mutation load in cancer-associat

28 mean follow-up of 3.8 years (range, 0-9.4 years), there was no significant difference in overall mortality or cause of mo

29 treated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the add

30 There was no significant difference in P1NP with either SPI or SP suppl

31 There was no significant difference in recipient mortality at 30 days,

32 s (26.8% vs. 17.1%; P = 0.007), respectively, but there was no significant difference in reduction between class 1 and 2

33 There was no significant difference in response rates between cisplatin

34 There was no significant difference in striatal Kicer between the bipol

35 There was no significant difference in survival between patients in Gro

36 There was no significant difference in the 5-year primary composite out

37 There was no significant difference in the 6-minute walk test between t

38 There was no significant difference in the change in the Physical Compo

39 In contrast, there was no significant difference in the DOX concentrations between t

40 There was no significant difference in the incidence of serious adverse

41 There was no significant difference in the levels of inhibition of UVB-

42 There was no significant difference in the primary end point between tr

43 There was no significant difference in the punctum diameter among the 3

44 ort of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failur

45 There was no significant difference in the risk of DFS events (hazard r

46 Results There was no significant difference in the size or shape of ablations c

47 There was no significant difference in the time to mortality between th

48 Comparing tIOLs vs PCRIs, there was no significant difference in the UCDVA, BCDVA, and UCNVA.

49 There was no significant difference in weight gain at 6, 12, or 18 mont

50 nts met macular laser criteria at a mean of 19.5 weeks with no significant difference in the frequency of IAIs before or